Invivo therapeutics announces 75% target enrollment achieved for the inspire 2.0 spinal cord injury study

Cambridge, mass.--(business wire)--invivo therapeutics holdings corp. (nasdaq: nviv), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has enrolled 15 patients with acute spinal cord injury into the inspire 2.0 study, or 75% of the total 20-patient enrollment target for the study. the inspire 2.0 study is a randomized, controlled trial (20-patient, 10 subjects in each study arm), that is designed
NVIV Ratings Summary
NVIV Quant Ranking